Cancer Platinum Resistance Detection and Sensitization Method
The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
Attached files:Patents:US 20,110,166,095
Inventor(s):
LANCASTER JOHNATHAN M [US]; MARCHION DOUGLAS C [US]; CHEN DUNG-TSA [US]
Type of Offer:
Licensing
« More Biotech Patents